Merck being hit hard by generic versions of its respiratory therapeutic Singulair, which has generated $44+ billion since its 1998 launch.
The story here:
Merck being hit hard by generic versions of its respiratory therapeutic Singulair, which has generated $44+ billion since its 1998 launch.
The story here: